Journal
MOLECULAR PHARMACEUTICS
Volume 15, Issue 9, Pages 4226-4234Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.8b00648
Keywords
caffeic acid; functional foods; lignin; mucosal adjuvant; nasal vaccine; polyphenol
Funding
- JSPS KAKENHI [15K18935, 18K06798, 15K18701, 16K08415, 16H01373]
- Japan Agency for Medical Research and Development (AMED) [17fk0108223h0002, 17ek0410032s0102, 17fk0108207h0002, 17ak0101068h0001, 17gm1010006s0101]
- Grants-in-Aid for Scientific Research [16H01373, 15K18935, 15K18701, 18K06798, 16K08415] Funding Source: KAKEN
Ask authors/readers for more resources
Infections remain a major threat to human lives. To overcome the threat caused by pathogens, mucosal vaccines are considered a promising strategy. However, no inactivated and/or subunit mucosal vaccine has been approved for human use, largely because of the lack of a safe and effective mucosal adjuvant. Here, we show that enzymatically synthesized polymeric caffeic acid (pCA) can act as a potent mucosal adjuvant in mice. Intranasal administration of ovalbumin (OVA) in combination with pCA resulted in the induction of OVA-specific mucosal IgA and serum IgG, especially IgG1. Importantly, pCA was synthesized from caffeic acid and horseradish peroxidase from coffee beans and horseradish, respectively, which are commonly consumed. Therefore, pCA is believed to be a highly safe material. In fact, administration of pCA did not show distinct toxicity in mice. These data indicate that pCA has merit for use as a mucosal adjuvant for nasal vaccine formulations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available